Skip to Content
Stock Analyst Update

Pfizer Posts Strong Q1 Buoyed by COVID-19 Sales

We expect sales will fall substantially after 2022, limiting the impact on our valuation.

Mentioned: ,

Pfizer (PFE) reported solid first-quarter results buoyed by strong COVID-19 vaccine sales, but we don’t expect any major impact to our fair value estimate based on the outperformance. While the COVID-19 vaccine sales are providing a major lift to sales and earnings in 2021 and likely into 2022, we expect sales will fall substantially after 2022, limiting the impact on our valuation. However, the amazing speed to market of a vaccine with excellent efficacy and safety shows Pfizer’s innovative power, a core pillar in the firm’s wide moat.

In the quarter, total sales increased 42% (up 8% excluding COVID-19 vaccine sales), and we expect steady growth over the next three years excluding the COVID-19 vaccine sales. COVID-19 vaccine sales contributed $3.5 billion in the quarter and are guided to be almost $26 billion in 2021, above previous guidance of $15 billion and ahead of our $23 billion estimate. We expect increasing supply, authorization in new age cohorts (ages 12-15 in May in the U.S., followed by almost all ages in the second half of 2021) and booster data to drive robust sales through 2022. Also, we expect the booster data will drive annual sales after 2022 of close to $2 billion with a focus on high-risk patients.

Outside of COVID-19 vaccines sales, Pfizer largely performed well. Top drugs Eliquis (cardiovascular), Vyndaqel (rare disease), and Xeljanz (immunology) all posted strong gains based on leading efficacy driving market share gains. However, cancer drug Ibrance fell 1% as economic hardships (likely related to the pandemic) are increasing the need for Pfizer assistance programs, but this should reverse as the pandemic eases. Also, pneumococcal vaccine Prevnar fell 57% in U.S. adults, where guidance against co-administration with COVID-19 vaccines pressured results, but a new co-administration study of next-generation Prevnar 20 with the COVID-19 vaccine (data later in 2021) should help reinvigorate the franchise. 

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Damien Conover does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.